Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Clin Rheumatol. 2010 Jun;29(6):619-24. doi: 10.1007/s10067-010-1376-8. Epub 2010 Jan 27.
Intra-articular hyaluronic acid has been used in treatment of patients with knee osteoarthritis. Though its effect on pain has been well studied, it is not clear how it affects the articular cartilage. This is a preliminary study to evaluate the kinetics of urinary collagen type-II C-telopeptide (CTX-II) as a biomarker of collagen breakdown in response to intra-articular hyaluronic acid injection in patients with symptomatic knee osteoarthritis. Intra-articular injections of hyaluronan were administered to ten patients with symptomatic knee osteoarthritis. Urine collection for urinary CTX-II was obtained at baseline, before each injection and once every other week for a total of 6 months. Urine CTX-II was measured using a CartiLaps(c) ELISA kit. There was a statistically significant increase (p = 0.0136) in CTX-II a week after the third intra-articular injection of hyaluronic acid (6,216 ng/mmol +/- 4,428) compared with baseline (2,233 ng/mmol +/- 1,220). This increase in CTX-II was sustained throughout the entire 6 months follow-up period (repeated measures ANOVA, p < 0.015). This is the first study of changes in an osteoarthritis biomarker after intra-articular hyaluronic acid injections in patients with symptomatic knee osteoarthritis. Contrary to our initial hypothesis that CTX-II levels should decrease after intra-articular hyaluronic acid injections, we found a significant increase in urinary CTX-II levels that was sustained throughout the study. These observations suggest that intra-articular hyaluronic acid injections may accelerate cartilage breakdown in patients with symptomatic knee osteoarthritis. The responsible mechanisms are unknown and warrant further study.
关节内透明质酸已被用于治疗膝骨关节炎患者。尽管其对疼痛的作用已得到充分研究,但尚不清楚它如何影响关节软骨。这是一项初步研究,旨在评估尿型胶原 II 交联 C 端肽(CTX-II)作为生物标志物在有症状的膝骨关节炎患者中关节内透明质酸注射后胶原分解的动力学。向 10 例有症状的膝骨关节炎患者关节内注射透明质酸。在基线、每次注射前和每隔一周收集尿液用于 CTX-II,共 6 个月。使用 CartiLaps(c)ELISA 试剂盒测量尿 CTX-II。第三次关节内透明质酸注射后一周 CTX-II 显著增加(p = 0.0136)(6216ng/mmol +/- 4428)与基线相比(2233ng/mmol +/- 1220)。这种 CTX-II 的增加在整个 6 个月的随访期间持续存在(重复测量方差分析,p < 0.015)。这是首次在有症状的膝骨关节炎患者中进行关节内透明质酸注射后骨关节炎生物标志物变化的研究。与我们最初的假设相反,即关节内透明质酸注射后 CTX-II 水平应降低,我们发现尿 CTX-II 水平显著增加,且在整个研究期间持续存在。这些观察结果表明,关节内透明质酸注射可能会加速有症状的膝骨关节炎患者的软骨分解。其负责的机制尚不清楚,需要进一步研究。